{
    "clinical_study": {
        "@rank": "8499", 
        "arm_group": [
            {
                "arm_group_label": "Ondansetron", 
                "arm_group_type": "Experimental", 
                "description": "Ondansetron + cognitive behavioral therapy"
            }, 
            {
                "arm_group_label": "Topiramate", 
                "arm_group_type": "Experimental", 
                "description": "Topiramate + cognitive behavioral therapy"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo + cognitive behavioral therapy"
            }, 
            {
                "arm_group_label": "Ondansetron + Topiramate", 
                "arm_group_type": "Experimental", 
                "description": "Ondansetron + Topiramate + cognitive behavioral therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn whether ondansetron and topiramate either alone or in\n      combination is safe and effective in the treatment of alcohol dependence. This 13 week\n      out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are\n      post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will\n      receive ondansetron and topiramate either alone or in combination or a placebo coupled with\n      psychotherapy."
        }, 
        "brief_title": "Alcohol Dependency Study: Combining Medication Treatment for Alcoholism", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Alcoholism", 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "detailed_description": {
            "textblock": "This study is a 13 week clinical trial. During the 13 weeks participants receive placebo,\n      ondansetron and topiramate alone or in combination. During the 13 weeks participants come to\n      an outpatient clinic to receive the study medication, physical checks, and cognitive\n      behavioral therapy. The duration of the weekly visit is 3 hours. There is a 1, 2, and 3\n      month post-study follow up visit. Screening for this study is initially done over the\n      telephone and takes 15-20 minutes. If there is nothing found to make someone ineligible to\n      participate, they come to the out-patient clinic for a more thorough in-clinic screening."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Current diagnosis of alcohol dependence and drinking greater than or equal to 14\n             alcohol drinks/week for women and greater than or equal to 21 alcohol drinks/week for\n             men in the last 30 days.\n\n          -  Provide a written, informed consent.\n\n          -  Good physical health and must weigh within at least 40 kg and no more than 140 kg.\n\n          -  Literate in English and able to read, understand, follow instructions, and complete\n             questionnaires accurately.\n\n          -  Willingness to participate in behavioral treatments for alcoholism.\n\n          -  Provide evidence of stable residence in the last month prior to enrollment in the\n             study and have no plans to move during the next three months.\n\n        Exclusion Criteria:\n\n        Please contact site for additional information"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006205", 
            "org_study_id": "NIAAAJOH1052207A1", 
            "secondary_id": "R01AA013964"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ondansetron", 
                "description": "ondansetron (4 mcg/kg b.i.d)", 
                "intervention_name": "ondansetron + cognitive behavioral therapy", 
                "intervention_type": "Drug", 
                "other_name": "Zofran"
            }, 
            {
                "arm_group_label": "Topiramate", 
                "description": "topiramate (up to 300 mg/day)", 
                "intervention_name": "topiramate + cognitive behavioral therapy", 
                "intervention_type": "Drug", 
                "other_name": "Topamax"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "placebo", 
                "intervention_name": "Placebo + cognitive behavioral therapy", 
                "intervention_type": "Drug", 
                "other_name": "sugar pill"
            }, 
            {
                "arm_group_label": "Ondansetron + Topiramate", 
                "description": "ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)", 
                "intervention_name": "ondansetron + topiramate + cognitive behavioral therapy", 
                "intervention_type": "Drug", 
                "other_name": "zofran, topamax"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ondansetron", 
                "Topiramate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "alcoholism", 
            "alcohol addiction"
        ], 
        "lastchanged_date": "March 14, 2013", 
        "link": {
            "description": "(UVA CARE Website)", 
            "url": "http://www.medicine.virginia.edu/clinical/departments/psychiatry/sections/neurobiologicalstudies/uvacare"
        }, 
        "location": [
            {
                "contact": {
                    "email": "mcb3x@virginia.edu", 
                    "last_name": "Mindy Borszich", 
                    "phone": "888-882-2345"
                }, 
                "contact_backup": {
                    "email": "emj9c@virginia.edu", 
                    "last_name": "Eva Jenkins-Mendoza", 
                    "phone": "(434)243-0562"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22911"
                    }, 
                    "name": "University of Virginia Center for Addiction Research and Education"
                }, 
                "investigator": [
                    {
                        "last_name": "Bankole Johnson, DSc, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Nassima Ait-Daoud Tiouririne, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mcb3x@virginia.edu", 
                    "last_name": "Mindy Borszich", 
                    "phone": "888-882-2345"
                }, 
                "contact_backup": {
                    "email": "emj9c@virginia.edu", 
                    "last_name": "Eva Jenkins-Mendoza", 
                    "phone": "(434)243-0562"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23294"
                    }, 
                    "name": "University of Virginia Center for Addiction Research and Education"
                }, 
                "investigator": [
                    {
                        "last_name": "Bankole Johnson, DSc, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Nassima Ait-Daoud Tiouririne, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Combining Medications Treatment for Alcoholism", 
        "overall_contact": {
            "email": "mcb3x@virginia.edu", 
            "last_name": "Mindy Borszich", 
            "phone": "1-888-882-2345"
        }, 
        "overall_contact_backup": {
            "email": "emj9c@virginia.edu", 
            "last_name": "Eva Jenkins-Mendoza", 
            "phone": "(434) 243-0562"
        }, 
        "overall_official": {
            "affiliation": "University of Virginia", 
            "last_name": "Bankole Johnson, DSc, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Drinks per drinking day, Drinks per day, Percent Days Abstinent, BAC, CDT, GGT", 
            "measure": "Self-report measures of alcohol-related problems and consumption, Objective measures of alcohol consumption", 
            "safety_issue": "No", 
            "time_frame": "Throughout the study"
        }, 
        "reference": {
            "PMID": "15330732", 
            "citation": "Johnson BA. An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opin Pharmacother. 2004 Sep;5(9):1943-55. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006205"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Virginia", 
            "investigator_full_name": "Bankole Johnson", 
            "investigator_title": "Chair of Psychiatry and Neurobehavioral Sciences", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Pill Count, Q-LES-Q, SFQ, AASE, ADBS, OCDS, CIWA-Ar, CGI, TCI, MAC, AOQ, FHAM", 
            "measure": "Medication compliance, alcohol craving, social functioning, quality of life, alcohol withdrawal, attendance at psychosocial services, pre-morbid risk factors", 
            "safety_issue": "Yes", 
            "time_frame": "Throughout the study"
        }, 
        "source": "University of Virginia", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Bankole Johnson", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2005", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }, 
    "geocoordinates": {
        "University of Virginia Center for Addiction Research and Education": "37.541 -77.436"
    }
}